- Home
- XBIO vs GLTO Comparison
XBIO vs GLTO Comparison
Compare XBIO & GLTO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- XBIO
- GLTO
- Stock Information
- Founded
- XBIO N/A
- GLTO 2011
- Country
- XBIO United States
- GLTO Denmark
- Employees
- XBIO N/A
- GLTO N/A
- Industry
- XBIO Biotechnology: Pharmaceutical Preparations
- GLTO Biotechnology: Pharmaceutical Preparations
- Sector
- XBIO Health Care
- GLTO Health Care
- Exchange
- XBIO Nasdaq
- GLTO Nasdaq
- Market Cap
- XBIO 6.3M
- GLTO 6.5M
- IPO Year
- XBIO N/A
- GLTO 2020
- Fundamental
- Price
- XBIO $4.24
- GLTO $5.13
- Analyst Decision
- XBIO Hold
- GLTO Buy
- Analyst Count
- XBIO 1
- GLTO 1
- Target Price
- XBIO N/A
- GLTO $10.00
- AVG Volume (30 Days)
- XBIO 11.0K
- GLTO 19.9K
- Earning Date
- XBIO 11-12-2024
- GLTO 03-07-2025
- Dividend Yield
- XBIO N/A
- GLTO N/A
- EPS Growth
- XBIO N/A
- GLTO N/A
- EPS
- XBIO N/A
- GLTO N/A
- Revenue
- XBIO $2,523,427.00
- GLTO N/A
- Revenue This Year
- XBIO N/A
- GLTO N/A
- Revenue Next Year
- XBIO N/A
- GLTO N/A
- P/E Ratio
- XBIO N/A
- GLTO N/A
- Revenue Growth
- XBIO 7.15
- GLTO N/A
- 52 Week Low
- XBIO $2.78
- GLTO $4.40
- 52 Week High
- XBIO $5.20
- GLTO $23.50
- Technical
- Relative Strength Index (RSI)
- XBIO 53.05
- GLTO 47.84
- Support Level
- XBIO $3.93
- GLTO $4.60
- Resistance Level
- XBIO $4.32
- GLTO $5.98
- Average True Range (ATR)
- XBIO 0.25
- GLTO 0.40
- MACD
- XBIO 0.01
- GLTO 0.02
- Stochastic Oscillator
- XBIO 84.31
- GLTO 38.33
About XBIO Xenetic Biosciences Inc.
Xenetic Biosciences Inc is a biopharmaceutical company focused on advancing immune-oncology technologies addressing cancers. The company is also engaged in progressing XCART, a personalized CAR T platform technology. The Company's DNase platform is designed to improve outcomes of existing treatments, including immunotherapies, by targeting neutrophil extracellular traps (NETs), which have been implicated in cancer progression and resistance to cancer treatments. The company also has oncology therapeutic investigational drug candidate XBIO-101 for the treatment of progestin-resistant endometrial cancer.
About GLTO Galecto Inc.
Galecto Inc is a clinical-stage biotechnology company developing therapeutics designed to target the biological processes that lie at the heart of fibrosis and impact a broad range of fibrotic and related diseases, including cancer. Its initial focus is on the development of small-molecule inhibitors of galectin-3 and lysyl oxidase-like 2, or LOXL2. Its product candidate GB0139 is for the treatment of severe fibrotic lung diseases such as idiopathic pulmonary fibrosis, or IPF, a life-threatening progressive fibrotic disease of the lung. Its product GB1211, a selective oral galectin-3 inhibitor for the treatment of fibrosis related to non-alcoholic steatohepatitis, or NASH, and GB2064, a selective oral inhibitor of LOXL2 that it initially plans to develop for the treatment of myelofibrosis.